Skip to contentpdufa.bio

CorMedix: 2 Complete Response Letters

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

The FDA's CRL release (openFDA transparency/crl, last updated 2026-11-18; snapshot read 2026-11-21) holds 2 Complete Response Letters to this company, dated 2021 to 2022, all on one application. The FDA releases letters selectively, so this may not be every letter the company received. Printed in the release as: CorMedix Inc. (2).

Grouped on the company name as openFDA prints it, with capitalization, accents, punctuation and corporate-form words (Inc., LLC, Ltd., Limited, Corp., SA, USA and the like) ignored; each row shows the name as printed. A misspelled name forms its own group, and a letter printed with a heading or a bare corporate-form word where the name should be is on no company page, so a count here can be lower than the letters the release holds for a company. Facts only: no view on any outcome.

Letter dateApplicationName as printedopenFDA statusOrange Book approval after the letterSections the letter names
August 4, 2022NDA 214520CorMedix Inc.ApprovedDefencath, November 15, 2023none read
February 26, 2021NDA 214520CorMedix Inc.ApprovedDefencath, November 15, 2023none read

How each column is made: the letter date and the PDF are the FDA's release; "openFDA status" is openFDA's approval_status field as released; "Orange Book approval" is the earliest approval date the FDA's Orange Book products file (FDA files dated 2026-11-13) lists for the NDA, shown when it falls after the letter date and the letter is not on a supplement; BLAs are not in the Orange Book, so no date is shown for them; "sections" are the letter's own deficiency headings read from its PDF text layer, for letters dated 2024 or later whose PDF holds no other letter from the release ("none read" otherwise, or where no heading could be read).

Every company in the release · facts from all released CRLs · every released letter